Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Kidney Diseases Associated with Human Immunodeficiency Virus Infection
A Randomized, Controlled Trial of a Behavioral Weight Loss Program for HIV-Infected Patients
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection
Antiretroviral therapy for the prevention of HIV-1 transmission
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men
Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
Published by François RAFFI
Updated: 3 November, 2014
The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 eradication strategies. In this study, monkeys were started on suppressive anti-retroviral therapy on days 3, 7, 10 and 14 after intra rectal SIVMac251 infection. Treatment with ARV on day 3 blocked the emergence of viral RNA and proviral DNA in peripheral blood and also substantially reduced level of proviral DNA in lymph nodes and gastro-intestinal mucosa compared with treatment at later time points. In addition, treatment from day 3 abrogated induction of SIV-specific humoral and cellular immune responses. After discontinuation of ART following 24 weeks of fully suppressive therapy, virus rebounded in all animals, although the monkeys that were treated on day 3 exhibited a delayed viral rebound compared with those treated on days 7, 10 and 14. The time to viral rebound correlated with total viremia during acute infection and with proviral DNA at the time of ART discontinuation.
These data demonstrate that the viral reservoir is seeded rapidly after intra-rectal SIV infection of rhesus monkeys, during the eclipse phase, and before any detectable viraemia. This strikingly early seeding of the refractory viral reservoir raises important new challenges for HIV-1 eradication strategies.